On improving the safety of new direct acting oral anticoagulants
One of the main causes of death and disability in the world are the thrombotic complications. Using of anticoagulants is the effective method of preventing of these life-threatening conditions. However, the use of anticoagulants involves a significant risk of the bleeding. Safety of anticoagulants predominately are determined by the availability of specific antidotes. Until now new oral directly acting anticoagulants do not have any specific antagonists. Idarutsizumab is the dagibatran-specific antagonist which increases its safety.